Drugs / AVT32-DRL_PB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07475572 | Jun 2026 → Oct 2027 expected | melanoma | Alvotech Swiss AG | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVT32-DRL_PB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07475572 ↗ |
| Route | Intravenous | “administered intravenously” NCT07475572 ↗ |